Related Experiment Video
Updated: Jan 15, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases
Dhruv Ahuja1,2, Soo-Kyung Park1,3, Kuan-Hung Yeh4
1Division of Gastroenterology, Department of Medicine, University of California san Diego, La Jolla, California, USA.
Background:
Advanced therapies increase the risk of shingles in inflammatory bowel diseases (IBD).
Aim:
To compare the risk of shingles with different advanced therapies in patients with IBD.
Methods:
We identified patients with IBD who initiated treatment with tumour necrosis factor (TNF) antagonists, anti-integrins, anti-interleukins, Janus kinase (JAK) inhibitors, or sphingosine-1 phosphate receptor (S1PR) modulators between 2016 and 2022 and had follow-up for at least 1 year before and after treatment initiation. We estimated the incidence rate (IR per 100 person-year [PY]) of shingles (overall and complicated) and compared the risk with different advanced therapies through multinomial propensity score-based inverse probability of treatment weighting (IPTW), with propensity scores estimated through generalised boosted models, accounting for disease characteristics, healthcare utilisation, comorbidities and prior and concomitant medications. Weighted Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for multiple treatment comparisons.
Results:
We included 21,675 patients followed over 27 months. IRs per 100 PY of shingles and complicated shingles were: TNF antagonists 1.0/0.3, anti-integrin agents 1.4/0.4, anti-interleukins 1.2/0.5, JAK inhibitors 3.3/0.9 and S1PR modulators 2.0/1.0. After adjusting for confounding variables, JAK inhibitors were associated with higher risks of shingles than TNF antagonists (HR 2.19; 1.28-3.75), anti-integrins (HR 1.87; 1.12-3.14) and anti-interleukins (HR 1.70; 0.98-2.96).
Conclusions:
JAK inhibitors were associated with 1.7-2.2-fold higher risk of shingles than other advanced therapies.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF